검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Pneumococcal Conjugate Vaccine, Heptavalent (Pneumococcal Conjugate Vaccine, Heptavalent) Sanofi Pasteur, a Sanofi Company·HIV Infections 52 trials·t½ 12 h |
|---|---|
Overview Program | Pneumococcal Conjugate Vaccine, Heptavalent |
Overview Company | Sanofi Pasteur, a Sanofi Company |
Overview Modality | ADC |
Overview Target | HIV Infections |
Overview Indication | HIV Infections; Hepatitis B |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
PK/PD Half-life | 12 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).. Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate… |
Clinical OS | 18 |
Clinical Result source | ClinicalTrials.gov NCT00652951 |
Clinical Data Tier / Score | A · 25 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Pneumococcal Conjugate Vaccine, Heptavalent (Pneumococcal Conjugate Vaccine, Heptavalent) Sanofi Pasteur, a Sanofi Company·HIV Infections 52 trials·t½ 12 h |
|---|---|
Overview Program | Pneumococcal Conjugate Vaccine, Heptavalent |
Overview Company | Sanofi Pasteur, a Sanofi Company |
Overview Modality | ADC |
Overview Target | HIV Infections |
Overview Indication | HIV Infections; Hepatitis B |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
PK/PD Half-life | 12 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).. Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate… |
Clinical OS | 18 |
Clinical Result source | ClinicalTrials.gov NCT00652951 |
Clinical Data Tier / Score | A · 25 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교